biote Corp (BTMD) - Net Assets
Based on the latest financial reports, biote Corp (BTMD) has net assets worth $-47.95 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($89.03 Million) and total liabilities ($136.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check biote Corp PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-47.95 Million |
| % of Total Assets | -53.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | -1321.75% |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
biote Corp - Net Assets Trend (2019–2025)
This chart illustrates how biote Corp's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see biote Corp stock valuation.
Annual Net Assets for biote Corp (2019–2025)
The table below shows the annual net assets of biote Corp from 2019 to 2025. Also explore biote Corp (BTMD) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-50.40 Million | +50.69% |
| 2024-12-31 | $-102.20 Million | -179.65% |
| 2023-12-31 | $-36.55 Million | +37.29% |
| 2022-12-31 | $-58.27 Million | -1512.70% |
| 2021-12-31 | $4.12 Million | +124.16% |
| 2020-12-31 | $-17.07 Million | +48.14% |
| 2019-12-31 | $-32.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to biote Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1665400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | % |
| Other Comprehensive Income | $-29.00K | % |
| Total Equity | $-58.54 Million | 100.00% |
biote Corp Competitors by Market Cap
The table below lists competitors of biote Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
C I Systems
TA:CISY
|
$43.27 Million |
|
Lokotech Group AS
OL:LOKO
|
$43.29 Million |
|
AC S.A.
WAR:ACG
|
$43.29 Million |
|
EstechPharma Co. Ltd
KQ:041910
|
$43.30 Million |
|
AViTA Corporation
TWO:4735
|
$43.25 Million |
|
Histeel
KO:071090
|
$43.22 Million |
|
Mineralbrunnen Überkingen-Teinach GmbH & Co. KGaA
F:MUT3
|
$43.22 Million |
|
Metal Sky Star Acquisition Corporation Ordinary shares
NASDAQ:MSSA
|
$43.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in biote Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -105,928,000 to -58,539,000, a change of 47,389,000.
- Net income of 27,045,000 contributed positively to equity growth.
- Dividend payments of 1,727,000 reduced retained earnings.
- Share repurchases of 3,365,000 reduced equity.
- New share issuances of 142,000 increased equity.
- Other comprehensive income increased equity by 6,000.
- Other factors increased equity by 25,288,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $27.05 Million | +46.2% |
| Dividends Paid | $1.73 Million | -2.95% |
| Share Repurchases | $3.37 Million | -5.75% |
| Share Issuances | $142.00K | +0.24% |
| Other Comprehensive Income | $6.00K | +0.01% |
| Other Changes | $25.29 Million | +43.2% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares biote Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-4.35 | $1.35 | x |
| 2020-12-31 | $-2.25 | $1.35 | x |
| 2021-12-31 | $0.54 | $1.35 | x |
| 2022-12-31 | $-5.52 | $1.35 | x |
| 2023-12-31 | $-1.14 | $1.35 | x |
| 2024-12-31 | $-3.09 | $1.35 | x |
| 2025-12-31 | $-1.60 | $1.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently biote Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.07%
- • Asset Turnover: 1.79x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (112.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 19.36% | 4.60x | 0.00x | $24.58 Million |
| 2020 | 0.00% | 25.02% | 3.58x | 0.00x | $30.87 Million |
| 2021 | 790.76% | 23.40% | 2.57x | 13.17x | $32.21 Million |
| 2022 | 0.00% | -0.59% | 1.48x | 0.00x | $3.48 Million |
| 2023 | 0.00% | 1.79% | 1.19x | 0.00x | $6.26 Million |
| 2024 | 0.00% | 1.60% | 1.61x | 0.00x | $13.75 Million |
| 2025 | 0.00% | 14.07% | 1.79x | 0.00x | $32.90 Million |
Industry Comparison
This section compares biote Corp's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $603,309,672
- Average return on equity (ROE) among peers: -3.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| biote Corp (BTMD) | $-47.95 Million | 0.00% | N/A | $43.26 Million |
| Acadia Healthcare Company Inc (ACHC) | $2.90 Billion | 9.42% | 0.72x | $1.52 Billion |
| Addus HomeCare Corporation (ADUS) | $706.69 Million | 8.85% | 0.45x | $1.69 Billion |
| agilon health Inc (AGL) | $-232.03 Million | 0.00% | 0.00x | $1.50 Billion |
| Airsculpt Technologies Inc (AIRS) | $87.71 Million | -13.30% | 1.14x | $165.82 Million |
| Amedisys Inc (AMED) | $1.11 Billion | 10.72% | 0.79x | $3.32 Billion |
| AMN Healthcare Services Inc (AMN) | $170.84 Million | -71.51% | 1.28x | $624.22 Million |
| American Shared Hospital Service (AMS) | $15.99 Million | 6.89% | 1.80x | $8.87 Million |
| American Oncology Network Inc. (AONC) | $226.04 Million | -0.05% | 0.10x | $325.24 Million |
| Ardent Health Partners, Inc. (ARDT) | $1.05 Billion | 17.99% | 3.63x | $1.53 Billion |
| Astrana Health Inc (ASTH) | $-17.74K | 0.00% | 0.00x | $1.70 Billion |
About biote Corp
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with … Read more